CHICAGO – Accutane

, the powerful acne drug already known to cause birth defects, seems to raise the risk for potential heart and liver problems more than doctors expected, according to a new study.

The findings came from lab tests on 13,772 patients taking the popular acne drug and underscore the need to closely monitor people taking isotretinoin, which is sold as Accutane and in three generic versions. Abnormal results for cholesterol and liver function were more common than expected.

While those conditions can lead to problems over the long term, abnormal lab tests don’t necessarily mean patients will develop heart or liver problems, said study co-author Dr. Lee Zane of the University of California, San Francisco.

“An elevation in cholesterol doesn’t guarantee a heart attack. A high level of liver enzymes doesn’t mean cirrhosis of the liver,” Zane said.

Further studies would be needed to determine any long-term health effects, he said, but in the current study, most patients’ abnormal lab tests returned to normal when they quit taking the drug.

Patients usually take it for less than a year. It’s considered one of the most effective treatments for severe acne.

On March 1, the U.S. Food and Drug Administration began requiring patients and doctors to register their use of the drug, a program intended to stop birth defects.

Isotretinoin can cause brain and heart defects in infants if a woman takes it during or immediately before pregnancy. More than 71,000 patients have registered in the FDA’s registry. Women who take it must have pregnancy tests and use birth control or abstain from sex.

The new study found higher than expected percentages of patients developing these abnormal lab results.

Among patients with normal lab tests before they started taking the drug, 44 percent developed high levels of triglycerides. The package insert, by contrast, cites high triglycerides in 25 percent of patients.

Thirty-one percent of healthy patients in the study developed high cholesterol levels and 11 percent developed abnormal liver tests.

The patients ranged in age from 13 to 50 and were treated between March 1995 and September 2002. They were all members of the Kaiser Permanente health plan in northern California. The findings were published in Monday’s Archives of Dermatology.

The study won’t change medical practice because dermatologists already carefully test patients taking Accutane, said Dr. John Strauss, professor emeritus at the University of Iowa College of Medicine. Strauss is a former consultant for Roche Laboratories Inc., the maker of Accutane, he said.

Roche representatives did not reply to an e-mail seeking comment on the study.